Volume 23, Number 7—July 2017
Research
Concurrent Infection with Hepatitis C Virus and Streptococcus pneumoniae
Thomas J. Marrie, Gregory J. Tyrrell, Sumit R. Majumdar, and Dean T. Eurich1
Table 2
Manifestations and complications of IPD patients stratified by HCV infection, Alberta, Canada, 2000–2014*
| Characteristic | HCV-positive, no. (%) | HCV-negative, no. (%) | Fully adjusted OR (95% CI) | p value |
|---|---|---|---|---|
| In-hospital death | 57 (16.1) | 429 (14.8) | 1.71 (1.15–2.54) | 0.008 |
| Pneumonia | 304 (85.6) | 2,388 (82.5) | 0.82 (0.57–1.20) | 0.310 |
| Cellulitis | 24 (6.8) | 59 (2) | 3.40 (1.81–6.39) | <0.001 |
| Septic arthritis | 5 (1.4) | 46 (1.6) | 1.00 (0.35–2.86) | 1.000 |
| Endocarditis | 4 (1.1) | 24 (0.8) | 0.93 (0.27–3.21) | 0.910 |
| Empyema | 30 (8.4) | 188 (6.5) | 1.11 (0.69–1.80) | 0.660 |
| Renal failure requiring dialysis | 26 (7.3) | 94 (3.2) | 2.14 (1.23–3.72) | 0.007 |
| Liver failure | 21 (5.9) | 49 (1.7) | 2.70 (1.41–5.18) | 0.003 |
| Mechanical ventilation | 110 (31) | 575 (19.9) | 1.44 (1.07–1.94) | 0.017 |
| Peritonitis | 16 (4.5) | 29 (1.0) | 3.79 (1.75–8.17) | 0.001 |
| Meningitis | 6 (1.7) | 154 (5.3) | 0.38 (0.16–0.92) | 0.001 |
*HCV, hepatitis C virus; IPD, invasive pneumococcal disease.
1All authors contributed equally to this article.
Page created: June 19, 2017
Page updated: June 19, 2017
Page reviewed: June 19, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.